

Funding opportunity guidance for UK-Japan collaborative clinical trials on children and young people's (CYP) cancers

Overview

The UK National Institute for Health and Care Research (NIHR) and the Japan Agency for Medical Research and Development (AMED) are inviting applications for UK-Japan collaborative clinical trials into children and young people's (CYP) cancers.

Joint funding is anticipated to support up to 2 awards for collaborative UK-Japan CYP cancer clinical trials of between 3 and 5 years. The Japan-based component will be funded by AMED, and the UK-based component by the NIHR. The NIHR is committing a total of £2 million to support UK-based components. AMED is committing JPY 390 million (up to JPY 65 million per award per year) to support Japan-based components.

We welcome applications focused on innovative therapies to address the unmet needs of children, adolescents and young people with cancer, through research significantly strengthened by UK-Japan collaboration. We are inviting applications for collaborative trials targeting:

- solid tumours
- haematological cancers
- brain cancers where evidence is desperately needed to improve patient outcomes

It is essential that applications take into account relevant published and ongoing international research and demonstrate how the proposed research will build on the existing body of knowledge, with specific reference to each country.

Applicants must submit a full research proposal to both UK and Japanese application management systems for a single-stage joint UK-Japan assessment process. To assist funders with the coordination of peer review, applicants are required to submit pre-submission information (comprising a brief summary of the research proposal and a list of all participating organisations) by 16 December 2026, ahead of the final closing date. While this is not mandatory, your assistance will be valued to help in securing timely and appropriate peer review assessments.

Eligibility

Our aim is to fund up to 2 collaborative UK- Japan projects and achieve equity in the balance of country leadership. To achieve this, ideally 1 funded award would have a UK Principal Investigator and 1 a Japanese Principal Investigator. The equitable distribution of project roles and responsibilities between UK and Japan collaborators must be clearly described and justified in the application to demonstrate that there is an appropriate balance. At the point of funding, selected awards may be required to adjust, where feasible, to ensure that this equity has been achieved.

Applicants must ensure that they meet eligibility requirements specified by their respective funder and the research specification for this funding opportunity.

The UK-based component of the trial should fall within the clinical remit of the joint NIHR-MRC [Efficacy and Mechanism Evaluation \(EME\) Programme](#), while keeping in mind the unique circumstances outlined in this funding opportunity.

The Japanese component should align with the AMED programme remit. All Japanese applicants must consult the AMED website and comply with the requirements set out therein before submitting an application.

(https://www.amed.go.jp/koubo/03005/02/B_00021.html)

All proposals must describe a robust clinical evaluation that incorporates outcomes highly meaningful to patients, clinicians, and services in both the UK and Japan. For the EME Programme, this means establishing definitive clinical efficacy and safety.

In addition, for this funding opportunity:

- it is mandatory to have a nominated lead from both the UK and Japan: 1 should be designated as the overall responsible international lead applicant
- participation by researchers from other countries is also welcome when they add expertise to the trial, provided that their research and clinical costs are secured through alternative funding sources
- lead applicants must be employed by and based at non-commercial institutions
- lead applicants cannot be named as a lead applicant on more than 1 application to this funding opportunity
- lead applicants must demonstrate an appropriate level of experience and independence to be able to lead the proposed multicentre clinical trials without the need for mentoring support
- UK applicants can request funding for career development awards to support early and mid-career researchers as they work towards independence - this is typically 10-20% of the project budget alongside potential exchange visits or placements to Japan
 - this should be in line with what is needed in the applicant's area of research/field and where there is a need for developing research capacity and supporting research careers, that complements the proposed research
 - a Named Point of Contact (NPC) must be appointed to oversee the academic career development of those individual(s) undertaking the competitively awarded career development award(s) that is being supported via this funding opportunity - they will be the first point of contact for all NIHR Academy related communication and queries
- study teams must be multi-disciplinary, including, for example, clinical experts, technology developers, statisticians, trial methodologists, patient/carer representatives with lived experience of cancer and health economists (noting that while health economic evaluations are traditionally out of remit for the EME Programme, they are permitted if there is no prospect of onward effectiveness trials being plausible due to low patient numbers or other reasons that the applicants can justify)

- UK teams must demonstrate active patient and public involvement and engagement (PPI) in study co-design, co-creation and co-delivery
- if co-applicants are invited to be part of more than 1 application, each application must state why the same person is included, and the shared co-applicant must not divulge study-specific details between the teams
 - both teams must explicitly declare in their applications that they are aware a co-applicant is part of a competing application, and formally state that no study-specific details have been shared

We recognise that there may be changes in the research team during the award. These changes should be justified and agreed in discussion with funders during the lifetime of the award.

This funding opportunity does not support costs for the early development of research collaborations between participating countries. It is anticipated that collaborators within any application will already have established strong links.

We wish to encourage lasting and strong collaborations through this funding opportunity. We may consider costs relating to the exchange of personnel between international sites where this is linked to a specific research activity, of clear benefit to the study and of a short duration.

If your application is successful, NIHR will aim to contract your award more rapidly than usual to align with AMED's timeline. Please plan ahead with your organisation's Research Support and Finance offices to facilitate a project start date in October - December 2027.

Key dates

28 October 2026

Funding opportunity opening date

16 December 2026

Applicants submit information to expedite peer review process

17 February 2027

Funding opportunity closing date

June 2027

Application funding decisions made

December 2027

Award start date

Webinar

17 November 2026 at 10:30 UK time

The webinar will cover the remit and research specification for this funding opportunity, as well as the application process itself and the support and guidance available to applicants, plus hints and tips on preparing a strong application. There will be a Q&A session at the end for attendees to submit queries to an NIHR panel.

The whole webinar will be recorded and shared with registered attendees.

[Register for this webinar on Zoom](#)

Research specification

Each year, approximately 3,700 young people under the age of 25 are diagnosed with cancer in the UK (1,645 children aged 0–14, and 2,110 teenagers and young adults aged 15–24). Similarly, in Japan, approximately 4,300 young people under the age of 25 are diagnosed with cancer (1,905 children aged 0–14, and 2,427 teenagers and young adults aged 15–24).

Despite survival improvements, cancer remains the leading cause of disease-related mortality among children in developed nations. Furthermore, this vulnerable patient population frequently faces a “drug lag” or “drug loss”, experiencing significantly poorer access to novel therapies and clinical trials compared to adults.

The most common types of cancer in CYP differ biologically from adult malignancies, often with different natural histories and necessitating distinct, tailored treatment approaches. The burden of these treatments is also profound, with survivors frequently enduring severe physical, psychological, and social consequences decades later, many of which are life-changing or life-limiting. Additionally, young adults in the UK (aged 16–24) face unique systemic challenges. They often fall into the gap between paediatric and adult healthcare services, a disparity that can contribute to significantly prolonged diagnostic intervals.

The critical need to advance research in CYP cancers is reflected in the strategic priorities of both nations, with each formally embedding this area within their national health frameworks. This shared commitment is evidenced by Japan’s [10-year Strategy of Cancer Research](#) (2023) and the UK’s recently published [The National Cancer Plan for England: delivering world class cancer care](#) (February 2026). This funding opportunity directly supports the goals of both Nations’ cancer plans. Bringing together 2 large nations with strong cancer research infrastructure is expected to enable trials to address cancer types where the numbers of affected children would be too small in either nation alone.

This joint funding opportunity builds on a successful [UK-Japan symposium](#) hosted in Tokyo in February 2026. The symposium, which included researchers and patients from the UK and Japan, identified key priorities and capacity-strengthening needs in CYP cancer research in both countries, and facilitated the development of research topics for future collaboration. This partnership will combine the UK and Japan’s mutual strengths, ideas, expertise, and infrastructure to improve the lives of CYP with cancer who currently have limited options for

cancer prevention, diagnosis and treatment. Non-attendance at the Tokyo meeting does not preclude researchers from applying to this funding opportunity.

Funding opportunity scope

This joint NIHR-AMED funding opportunity invites applications to evaluate innovative interventions, tests, technologies or treatments for children, adolescents and young people with cancers that require, or are significantly strengthened by, UK-Japan international collaboration. We are looking to fund UK-Japan collaborative cancer trials targeting paediatric and young people's cancers. Trials may evaluate interventions at any point in the clinical pathway, from early detection and diagnosis to active treatment, post-treatment recovery, and palliative or end-of-life care.

We are particularly interested in UK-Japan collaborative cancer trials targeting

- solid tumour cancers
- haematological cancers
- brain cancers

and particularly where evidence is urgently needed to improve patient outcomes.

NIHR-MRC EME Programme

The NIHR-MRC EME Programme is supporting this joint funding opportunity which is specifically tailored to evaluate clinical efficacy and safety in children and young people's cancers. The aim of the NIHR-MRC EME Programme is to fund ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care.

This funding opportunity recognises that paediatric and young people's cancers represent rare indications with small patient populations. We welcome studies that can be adapted to accommodate the smaller sample sizes achievable in studies of rare diseases, including permitting health economic evaluation if there is no prospect of onward effectiveness trials being plausible due to low patient numbers. Standalone mechanistic projects or exploratory biomarker discovery analyses (such as proteomics or genome-wide association studies (GWAS)) are out of scope; however, nested, hypothesis-testing mechanistic sub-studies designed to explore the intervention's mechanism of action are welcomed but not mandatory.

See further information on the [remit of the EME Programme](#).

AMED Programme

The aim of the AMED programme is to support ambitious clinical trials in paediatric and young people's cancers that have the potential to establish new standards of care. In addition to demonstrating clinical efficacy, studies should address the long-term safety of interventions and consider the developmental, life-stage and psychosocial characteristics of this population, including the reduction of late effects and the preservation of quality of life. Ultimately, the AMED programme seeks to generate high-quality evidence that will contribute to standard treatment approaches and support the development of clinical practice guidelines for

paediatric and young people's cancers. Research involving animals or animal tissue are out of scope for this NIHR-AMED funding opportunity.

Study design

To address the rarity of cancers among children and young people, this joint funding opportunity supports clinical trials at Phase IIb or Phase III. Phase IIb trial designs are welcomed where they are likely to serve as the definitive trial leading directly to a change in clinical practice, with no requirement for an onward Phase III trial due to the small patient population. Consequently, health economic evaluations are expected for all Phase III proposals, and are permitted and expected for definitive Phase IIb trials. Randomised study designs are encouraged.

For all submissions, applicants should demonstrate clear, published prior proof of concept in humans showing that the intervention has made a positive difference to the primary clinical outcomes of interest (evidenced, for example, by smaller clinical trials, systematic reviews, meta-analyses, or consistent case series).

For Phase III trials, there should be previously published evidence of the intervention's clinical efficacy. The primary focus of this funding opportunity is clinical trial completion utilising an accredited UKCRC-registered Clinical Trials Unit (CTU) or equivalent Japanese infrastructure (for example Clinical Research Core Hospitals, Academic Research Organisation (AROs), and related support systems). However, Phase IIb applicants may choose to include a modest, nested component of hypothesis-driven work to explore the intervention's mechanism of action, though this is not mandatory.

Applicants should propose a clinical trial design that answers their identified research question in the most robust and efficient way, and we encourage innovative methodologies. While this funding opportunity prioritises initiating new clinical trials, we will consider proposals to add new treatment arms to existing trials for rare cancers that would be significantly advanced by this joint funding opportunity. Standalone pilot and feasibility studies are not eligible for funding under this funding opportunity. Where appropriate, the inclusion of additional trial arms in other countries is permitted, provided their associated clinical and research costs are fully secured through alternative sources to this funding opportunity.

To ensure the highest standards of trial delivery and data integrity, it is essential that an accredited UKCRC-registered Clinical Trials Unit (CTU) be formally engaged and costed into the application. It is recommended that applicants also include equivalent Japanese clinical trial infrastructure. To meet the reciprocal criteria, each country must contribute at least 20% of the total participant cohort to ensure that the clinical data is robust and applicable to both populations. Trials should take into account NHS care pathways in the UK and equivalent specialised paediatric oncology clinical networks in Japan.

Developing academic research capacity and research careers - UK component only

We are committed to growing international research capacity and expertise to enable a shift in the CYP cancer research landscape; developing the next generation of researchers with the right skills and expertise to conduct and lead world leading collaborative CYP cancer clinical trials.

We want to inspire, support and develop new communities of researchers, bringing new ideas and thinking from a much broader range of disciplines, specialisms, backgrounds, geographies and sectors.

As part of the application, UK applicants can request funding for career development awards for early and mid-career researchers as they work towards independence. This should be in line with what is needed in the applicant's area of research/field and where there is a need for developing research capacity and supporting research careers. We have developed a framework of career development opportunities, which sets out a common naming convention for the different career development award types across each career stage (internship, predoctoral, doctoral, postdoctoral etc.), along with the core elements of what each award should offer, which we expect applicants to follow.

One of the key principles of the framework is that all NIHR career development awards should be advertised nationally via an open competition (for example advertised via an appropriate publicly accessible website) to ensure equity of access and opportunity, rather than pre-identifying and naming individuals at the application stage. We are committed to supporting and increasing opportunities for groups and professions that are currently underrepresented within the NIHR.

As part of this funding opportunity, funds can also be requested to support potential exchange visits/placements for UK based early and mid-career researchers to Japan to facilitate the sharing and upskilling of knowledge, skills and best practice, where there is a clear need/benefit and justification.

Please include a Research Capacity Development Plan in the 'Research plan' section of the application, under 'Application guidance'.

Benefits of embedding research capacity development

UK-based individuals whose academic career development is being supported through this funding opportunity have the opportunity to gain membership of the NIHR Academy. They will have access to our wider NIHR Academy programme of support, events and activities and must meet all the following criteria:

- be undertaking a formal career development award
- have been competitively awarded their career development award via an open competition
- have a training and development plan in place following their appointment
- have a defined end point (such as an application for further funding)
- receive at least 25% funding through the NIHR funding opportunity for salary/stipend over the lifetime of the individual's career development award

Funding

UK applicants can apply for a proportion of the overall project budget to be spent on research capacity development. It is usually anticipated that this will equate to no more than 10-20% of the overall funds requested. However, we will consider each application on an individual basis.

The focus of the capacity building component and associated funding should be on establishing individual funded career development awards and associated research training and academic career development activities in line with the principles outlined in the [NIHR framework of career development opportunities](#).

1. Career development awards

For each award please include:

- salary, stipend or a fixed amount to allow individuals to undertake these posts without financial burden
 - it is important to consider whether a stipend is the most appropriate form of payment across career stages, particularly for more experienced practitioners
- Personal training and development plan and ringfenced budget that is tailored to the individual's needs and their research career
 - this may include, for example, costs related to attending conferences, undertaking formal training courses, or costs for working with people and communities
- course fees if career development awards support masters or PhD students, course fees at the UK home rate should be covered by the funding

2. Wider academic career development activities

A small proportion of funding can also be requested to support potential exchange visits/placements for UK based early and mid-career researchers to Japan to facilitate the sharing and upskilling of knowledge, skills and best practice, where there is a clear need/benefit and justification.

Inclusive research

You must detail how you have considered inclusive research design and sex and gender throughout the whole research lifecycle and provide information on any associated costs.

For full details see:

[Research inclusion funding application guidance](#)

We encourage applications which include recruitment from geographic populations that have historically been underserved by research activity in this field. People with protected characteristics must be as well represented in the trials as they are in society generally, and you should articulate mechanisms to ensure this in your application.

The involvement of consumers, including patients and the public, must be embedded throughout the research lifecycle. This includes informing the research priorities and needs, the design of clinical trial plans, during the conduct of the clinical trial and dissemination of research findings. Applications are expected to evidence strong patient and public involvement and engagement in the development of the clinical study protocol, particularly around the acceptability of the proposed treatment strategies and the feasibility of recruitment.

Pathways to impact

We are focused on the impact of the research we fund. We ask applicants to consider the timing and nature of deliverables in your proposal and encourage you to maximise the impact of your research by explaining how you will mobilise knowledge and ensure that it is useful and relevant to stakeholders in both countries, such as:

- patients and the public
- clinicians
- policy makers
- public health officers
- special interest groups
- charities
- community audiences
- other stakeholders

Application guidance

Please read all the following guidance in addition to the information below, to help you complete your application:

- [domestic full application guidance](#): this lists the fields that appear in the awards management system and explains what information you need to include for each one
- [funding assessment criteria](#): this describes the 7 criteria you must address in your full application
- the additional assessment criteria for research capacity development for the UK component (see assessment process section)
- [research inclusion guidance](#): it is important that you fully consider inclusion throughout the whole research life cycle
- [finance guidance for applicants](#): this helps you complete the finance section of the full application form and explains which costs are eligible

Lead applicant and research team

The application on the NIHR Awards Management System (AMS) should contain the UK-based lead and co-applicant details, and the Japan-based team should be added to the [e-Rad application system](#).

Detailed research plan

The detailed research plan is the main part of your application. Please write a maximum of 20 A4 pages for your detailed research plan (Arial size 12 font) and PDF the document before uploading it to preserve its length and format.

General guidance on completing all the following headings of your detailed research plan is in the [domestic full application guidance](#), with some more specific guidance for this funding opportunity below.

Throughout the detailed research plan, you should clearly specify which work packages, activities, or research components will take place in the UK and Japan, and identify which research team members in each country will be responsible for delivering them.

The following headings should be used:

Background and rationale

Describe the background and rationale for the proposed research. You should include:

- a description of how your project addresses the aims of the funding opportunity such as why a UK-Japan collaborative approach is necessary to successfully deliver the trial
- an explanation of the health or social care problem being addressed and how the project responds to gaps in knowledge and addresses inequalities or the needs of under-served populations, or both, in the UK and Japan
- an explanation of why your research is important, how it addresses a high priority for Japan, the UK, and the impact it could have. Please consider the impact the research could have on those most affected, for example: members of the public and communities; practitioners; service planners and decision makers; workforce and policy makers and others
- information on how the existing literature or evidence base, or both, supports your application, and how it fills an evidence gap. We will only fund primary research where the proposed research is informed by a review of the existing evidence

Aims and objectives

Please refer to the domestic full guidance for details.

Methodology/plan (under the '4. Your research team' sub-heading, please include all members of your team in the UK and Japan)

Knowledge mobilisation, dissemination and impact

Please refer to the domestic full guidance for details.

Project management

You should clearly set out the equitable, joint UK - Japan project management and oversight plans. Include identified risks and mitigations to overcome potential challenges working across the 2 countries, given the planned research and understanding of different regulatory contexts.

Please also clearly describe and justify:

- which country, organisation and individual will act as the primary sponsor, working with a Clinical Trials Unit (where applicable) to manage protocols, global regulatory submissions, and overall trial liability
- where the master electronic database and data management activities will be located
- which country, organisation and individual will undertake the key trial coordination activities across both countries
- the specific roles and responsibilities of all members of the UK and Japan research teams

Developing academic research capacity and research careers - UK applicants only

Please describe your research capacity development plan here. Please provide an explanation of:

- the need or critical skill gap for building research capacity and expertise within the proposed area of research/field, and what you are proposing to fund and why
 - we are committed to supporting and increasing opportunities for groups and professions that are currently underrepresented within the NIHR
- the number and type of career development award(s) you are proposing to support and fund - please follow the naming convention and principles outlined in the [framework of career development opportunities](#)
- what research activities the career development award holder(s) will undertake over the lifetime of their award, and how these will act as suitable training vehicles?
- the plans in place to support the award holders training needs (for example appropriate mentoring, skills development etc)
- the quality and suitability of the research training environment for hosting individual(s) undertaking a career development award
- an understanding of your processes for competitively recruiting and appointing to the proposed funded career development award(s), and a broad outline of the timelines for this
 - please refer to the guidance for advertisement and recruitment within the [framework of career development opportunities](#)
- how inclusivity will be embedded in supporting diverse career paths and individuals' research careers
- who will act as the [Named Point of Contact \(NPC\)](#)? The NPC must be listed in the application, and can be the lead applicant, or a co-applicant, with relevant experience, or an existing dedicated career development lead from the contracting or collaborating institutions

Intellectual property and commercialisation

Please provide details on IP/legal frameworks and considerations and clarify the plans for future IP ownership and use by research team collaborators and any industry collaborators in both countries, particularly for any emerging technologies.

Budget

In your application to the NIHR awards management system, please enter the UK costs only in the 'Budget' section.

Please note, research costs do not need to be equally distributed between the UK and Japan.

For NIHR costs, please see [NIHR finance guidance](#) for more information, including details about specific funding rates.

Uploads

Please use the following information to complete the 'Uploads' section of your application.

Flow diagram (not required)

You do not need to upload a flow diagram as part of this application.

Logic model (not required)

You do not need to upload a logic model as part of this application.

Gantt chart of project management plan (mandatory)

Upload a Gantt chart outlining key milestones, activities and deliverables that will be completed throughout the duration of the award.

References (mandatory)

Upload 1 single-side A4 page of references as a PDF document. Please use Arial size 12 font.

Flexible upload (mandatory)

Upload a PDF which lists:

- the names, affiliations, roles and responsibilities, % FTE time commitment and ORCID reference for the Japan-based lead applicant and co-applicants
- the research costs being requested from AMED for the Japan-based component of the research proposal

Please check you have also uploaded a PDF of the detailed research plan (no more than 20 A4 pages Arial size 12 font).

Application process

Find out how to apply for this funding opportunity and what you need to do to get your application ready.

How to apply

Applicants in Japan and the United Kingdom (UK) must each submit their respective portions of the application through their designated funder's application system. For this funding opportunity, UK-based researchers can only request funding from the NIHR and Japan-based researchers can only request funding from AMED.

Pre-submission information for peer review

UK lead applicants should open an application in the NIHR awards management system before 16 December 2026 and will be notified to download and complete a form, providing:

- the names of all universities and institutes in the UK and Japan involved in the full application
- a brief summary of the research proposal, limited to 250 words

The completed form should be uploaded to the awards management system by 16 December 2026. NIHR will use this information solely to identify suitable expert peer reviewers who have no conflicts of interest with the full application.

(This task is not mandatory, and you will still be able to submit your full application without completing it).

Full application deadline

The closing date is 17 February 2027 at 1pm in the UK on the NIHR awards management system and at 5pm in Japan in the AMED application system. Applications received after these times on the closing date will not be considered.

UK applicants

You will need to [log in to the NIHR awards management system to apply](#). You will need to create a new account if you do not have one already.

The UK lead applicant must submit the UK-based component of the application. As part of the application they must also upload a PDF to the NIHR awards management system using the 'Flexible upload' option which lists: the Japanese team, roles and costs for the Japanese components (see the 'Flexible upload (mandatory)' section).

Japan applicants

The Japan lead applicant must submit the Japan-based component to the [e-Rad application system](#). They must also provide the UK lead with the PDF of the Japan-based research team, roles and the research costs in Japan, as described above.

Download application form template

You can download a Word document template of the NIHR application form below. Please use this template as a guide only, to help you prepare your application. For example, to see how many characters are accepted in each section and to see how information in the form is laid

out. Please do not try to use this as an application form; it cannot be submitted as an application. You must submit your application online via the NIHR awards management system and the AMED system.

Application support

Research Support Service

Got a research idea and not sure how to turn it into a funding application? The free NIHR Research Support Service (RSS) supports researchers in England to apply for funding, and to develop and deliver clinical and applied health, social care and public health research post award. [Find out how the RSS can help you.](#)

CTU involvement

It is essential that studies involving a clinical trial have engaged with an accredited Clinical Trials Unit in the UK and equivalent in Japan.

Assessment process and additional assessment criteria

You are advised that the NIHR and AMED are custodians of public funds and value for money is a key criterion that peer reviewers and funding committee members will assess applications against.

These [funding assessment criteria](#) will be used to assess your proposal. There is additional assessment criteria for Research Capacity Development - UK components only.

- The quality and relevance of the research capacity development proposal to strengthen international clinical trials capacity and expertise; including through mobility for knowledge exchanges and the provision of training which supports diverse career paths and promotes equality, diversity and inclusion have been considered and justified.

A peer review and rebuttal stage for applicants will be undertaken on applications submitted, and prior to the funding committee's final assessment using the above criteria. Information submitted before the full application deadline will be used to identify appropriate peer reviewers. Applicants will be invited to respond to peer reviewer feedback in April 2027.

A jointly convened AMED and NIHR committee will assess applications against the funding assessment criteria and feedback will be provided to applicants irrespective of the outcome.

Funding recommendations will be formally approved by each funder prior to joint lead applicants being notified by the respective national funder. NIHR will notify the UK lead applicant and AMED will notify the Japan lead applicant of the final outcome. Individual award grant/contract arrangements and the subsequent payments will be arranged directly with NIHR to the UK lead institute, and AMED to the Japan lead institute. The funding decisions are final and not subject to appeal.

Our commitment to inclusion

We are committed to [creating a diverse and inclusive culture](#). We encourage applications from people from all backgrounds and communities bringing diverse skills and experiences.

Additional support

We are committed to removing barriers to inclusion wherever possible. We want to maximise the inclusion of disabled people and individuals with long term health conditions. We want to make sure our processes are as inclusive as possible and this might mean we need to make adjustments to the application process or for the undertaking of the award if successful.

If you need to discuss a reasonable adjustment to support completion of your application, please contact internationalapplications@nihr.ac.uk.

You should not disclose detailed information of reasonable adjustments required to undertake the award in your application. You should include costings for reasonable adjustment that you, or co-applicants may require, in your budget. We will discuss this with you further if your application is successful. See our [finance guidance](#) for more information.